Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Antisense to Epstein Barr Virus-encoded LMP1 does not affect the transcription of viral and cellular proliferation-related genes, but induces phenotypic effects on EBV-transformed B lymphocytes

Abstract

It is generally accepted that Epstein–Barr virus (EBV) latent genes EBNA-2, EBNA-3A, -3C, EBNA-LP and LMP1 are essential for growth transformation and immortalization of B lymphocytes. Among these genes, LMP1 plays a key role in the survival and dissemination of the infected B cells by inducing anti-apoptotic genes and surface expression of several activation antigens and adhesion molecules. We have previously shown that antisense oligodeoxynucleotides directed to LMP1 mRNA, effectively suppress LMP1 gene expression and substantially reduce B95.8 cell proliferation. In this study, we have used antisense LMP1 oligomers to investigate whether LMP1 suppression might influence the expression of latent EBV genes with oncogenic potential, anti-apoptotic genes, or affect the phenotype of EBV-infected B95.8 cells. Our data show that LMP1 suppression does not affect the transcription of EBNA-2, EBNA-3A, -3B and -3C genes, or that of bcl-2 and mcl-1 anti-apoptotic genes. In contrast, consistent modifications in the expression of CD39, CD54, CD23, CD11 and CD10 molecules were observed in B95.8 cells after treatment with antisense LMP1. Our findings support the possibility for using LMP1 antisense oligomers as therapeutics in EBV-associated tumors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Baichwal VR, Sugden B . 1988 Oncogene 2: 461–467

  • Cohen JL, Wang F, Mannick J, Kieff E . 1989 Proc. Natl. Acad. Sci. USA 86: 9558–9562

  • D'Souza B, Rowe M, Walls D . 2000 J. Virol. 74: 6652–6658

  • Fahraeus R, Rymo L, Rhim JS, Klein G . 1990 Nature 345: 447–449

  • Farrell P . 1995 Trends Microbiol. 3: 105–109

  • Hammerschmidt W, Sugden B . 1989 Nature 340: 393–397

  • Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A . 1991 Cell 65: 1107–1115

  • Hu LF, Chen F, Zheng X, Ernberg I, Cao SL, Christensson B, Klein G, Winberg G . 1993 Oncogene 8: 1575–1583

  • Kaye K, Izumi KM, Kieff E . 1993 Proc. Natl. Acad. Sci. USA 90: 9150–9154

  • Kempkes B, Spitkovsky D, Jansen-Durr P, Ellwart JW, Kremmer E, Delecluse HJ, Rottenberger C, Bornkamm GW, Hammerschmidt W . 1995 EMBO J. 14: 88–96

  • Kenney JL, Guinness ME, Curiel T, Lacy J . 1998 Blood 92: 1721–1727

  • Kintner CR, Sudgen B . 1981 Nature 294: 458–460

  • Kulwichit W, Edwards RH, Davenport EM, Baskar J, Godfrey V, Raab-Traub N . 1998 Proc. Natl. Acad. Sci. USA 95: 11963–11968

  • Martin JM, Veis D, Korsmeyer SJ, Sugden B . 1993 J. Virol. 67: 5269–5278

  • Mattia E, Chichiarelli S, Hickish T, Gaeta A, Mancini C, Cunningham D, Van Renswoude J . 1997 Oncogene 15: 489–493

  • Miller G . 1990 Virology Fields BN, Knipe DM, Chanock RM (eds) pp 1921–1958 New York: Raven

    Google Scholar 

  • Nicholson LJ, Hopwood P, Johannessen I, Salisbury JR, Codd J, Thorley-Lawson D, Crawford DH . 1997 Oncogene 15: 275–283

  • Noguchi T, Ikeda K, Iamamoto K, Yoshida I, Ashiba A, Tsuchiyama J, Shinagawa K, Yoshino T, Takata M, Harada M . 2001 Br. J. Haematol. 114: 84–92

  • Patarroyo M, Beatty PG, Nillson K, Gahmberg CG . 1986 Int. J. Cancer 38: 539–547

  • Rowe M, Peng-Pilon M, Huen DS, Hardy R, Croom-Carter D, Lundgren E, Rickinson AB . 1994 J. Virol. 68: 5602–5612

  • Thorley-Lawson DA, Nadler LM, Bhan AK, Schooley RT . 1985 J. Immunol. 134: 3007–3012

  • Tomkinson B, Robertson E, Kieff E . 1993 J. Virol. 67: 2014–2025

  • Wang C, Liebowitz F, Gregory CD, Rickinson A, Larson R, Springer T, Kieff E . 1988 J. Virol. 62: 4173–4184

  • Wang D, Liebowitz D, Kieff E . 1985 Cell 43: 831–840

  • Wang F, Gregory CD, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson A, Kieff E . 1990 J. Virol. 64: 2309–2318

  • Wang S, Rowe M, Lundgren E . 1996 Cancer Res. 56: 4610–4613

Download references

Acknowledgements

This work has been partially supported by a contribution of the ‘Istituto Pasteur, Fondazione Cenci Bolognetti', University of Rome, ‘La Sapienza’.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Elena Mattia.

Additional information

This paper is dedicated to the memory of our dear friends and colleagues, Giuseppe Carruba and Franco Tato' prematurely deceased.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Masciarelli, S., Mattioli, B., Galletti, R. et al. Antisense to Epstein Barr Virus-encoded LMP1 does not affect the transcription of viral and cellular proliferation-related genes, but induces phenotypic effects on EBV-transformed B lymphocytes. Oncogene 21, 4166–4170 (2002). https://doi.org/10.1038/sj.onc.1205515

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205515

Keywords

This article is cited by

Search

Quick links